Literature DB >> 28385805

2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Rohit Aggarwal1, Lisa G Rider2, Nicolino Ruperto3, Nastaran Bayat2, Brian Erman4, Brian M Feldman5, Chester V Oddis1, Anthony A Amato6, Hector Chinoy7, Robert G Cooper8, Maryam Dastmalchi9, David Fiorentino10, David Isenberg11, James D Katz2, Andrew Mammen12, Marianne de Visser13, Steven R Ytterberg14, Ingrid E Lundberg9, Lorinda Chung10, Katalin Danko15, Ignacio García-De la Torre16, Yeong Wook Song17, Luca Villa3, Mariangela Rinaldi3, Howard Rockette1, Peter A Lachenbruch2, Frederick W Miller2, Jiri Vencovsky18.   

Abstract

To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus. Consensus was reached for a conjoint analysis-based continuous model using absolute per cent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0-100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (p<0.001). The response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute per cent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Dermatomyositis; Polymyositis; Treatment

Mesh:

Year:  2017        PMID: 28385805      PMCID: PMC5496443          DOI: 10.1136/annrheumdis-2017-211400

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  38 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Basic principles of ROC analysis.

Authors:  C E Metz
Journal:  Semin Nucl Med       Date:  1978-10       Impact factor: 4.446

Review 3.  Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider
Journal:  Rheum Dis Clin North Am       Date:  2002-11       Impact factor: 2.670

4.  Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology.

Authors:  N Ruperto; A Ravelli; A Pistorio; C Malattia; S Cavuto; L Gado-West; A Tortorelli; J M Landgraf; G Singh; A Martini
Journal:  Clin Exp Rheumatol       Date:  2001 Jul-Aug       Impact factor: 4.473

5.  Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy.

Authors:  G J D Hengstman; H J ter Laak; W T M Vree Egberts; I E Lundberg; H M Moutsopoulos; J Vencovsky; A Doria; M Mosca; W J van Venrooij; B G M van Engelen
Journal:  Ann Rheum Dis       Date:  2006-05-05       Impact factor: 19.103

6.  A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response.

Authors: 
Journal:  Arthritis Rheum       Date:  2007-03-15

Review 7.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Authors:  F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

Review 8.  Defining Clinical Improvement in Adult and Juvenile Myositis.

Authors:  Lisa G Rider; Edward H Giannini; Michael Harris-Love; Galen Joe; David Isenberg; Clarissa Pilkington; Peter A Lachenbruch; Frederick W Miller
Journal:  J Rheumatol       Date:  2003-03       Impact factor: 4.666

Review 9.  International consensus on preliminary definitions of improvement in adult and juvenile myositis.

Authors:  Lisa G Rider; Edward H Giannini; Hermine I Brunner; Nicola Ruperto; Laura James-Newton; Ann M Reed; Peter A Lachenbruch; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2004-07

10.  The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study.

Authors:  Nicolino Ruperto; Angelo Ravelli; Angela Pistorio; Virginia Ferriani; Immaculada Calvo; Gerd Ganser; Jurgen Brunner; Guenther Dannecker; Clovis Arthur Silva; Valda Stanevicha; Rebecca Ten Cate; Lisette W A van Suijlekom-Smit; Olga Voygioyka; Michel Fischbach; Ivan Foeldvari; Odete Hilario; Consuelo Modesto; Rotraud K Saurenmann; Marie-Josephe Sauvain; Iloite Scheibel; Danièle Sommelet; Lana Tambic-Bukovac; Roberto Barcellona; Riva Brik; Stephan Ehl; Mirjana Jovanovic; Jozef Rovensky; Francesca Bagnasco; Daniel J Lovell; Alberto Martini
Journal:  Arthritis Rheum       Date:  2008-01-15
View more
  26 in total

Review 1.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

2.  Inflammatory myopathies: Adult and paediatric experts unite for new response criteria.

Authors:  Joanna Collison
Journal:  Nat Rev Rheumatol       Date:  2017-05-04       Impact factor: 20.543

3.  Intravenous human immunoglobulin and/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies.

Authors:  Jean Marcos de Souza; Leonardo Santos Hoff; Samuel Katsuyuki Shinjo
Journal:  Rheumatol Int       Date:  2019-02-18       Impact factor: 2.631

4.  2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects.

Authors:  Lisa G Rider; Nicolino Ruperto; Angela Pistorio; Brian Erman; Nastaran Bayat; Peter A Lachenbruch; Howard Rockette; Brian M Feldman; Adam M Huber; Paul Hansen; Chester V Oddis; Ingrid E Lundberg; Anthony A Amato; Hector Chinoy; Robert G Cooper; Lorinda Chung; Katalin Danko; David Fiorentino; Ignacio García-De la Torre; Ann M Reed; Yeong Wook Song; Rolando Cimaz; Rubén J Cuttica; Clarissa A Pilkington; Alberto Martini; Janjaap van der Net; Susan Maillard; Frederick W Miller; Jiri Vencovsky; Rohit Aggarwal
Journal:  Rheumatology (Oxford)       Date:  2017-11-01       Impact factor: 7.580

Review 5.  Promising and Upcoming Treatments in Myositis.

Authors:  Lauren N Smith; Julie J Paik
Journal:  Curr Rheumatol Rep       Date:  2020-08-26       Impact factor: 4.592

6.  Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.

Authors:  Julie J Paik; Livia Casciola-Rosen; Joseph Yusup Shin; Jemima Albayda; Eleni Tiniakou; Doris G Leung; Laura Gutierrez-Alamillo; Jamie Perin; Liliana Florea; Corina Antonescu; Sherry G Leung; Grazyna Purwin; Andrew Koenig; Lisa Christopher-Stine
Journal:  Arthritis Rheumatol       Date:  2021-03-24       Impact factor: 10.995

Review 7.  Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options.

Authors:  Rachel Zeng; Stefanie Glaubitz; Jens Schmidt
Journal:  Neurotherapeutics       Date:  2022-04-08       Impact factor: 6.088

Review 8.  Role of Contrast-enhanced Ultrasound in the Evaluation of Inflammatory Arthritis.

Authors:  Chen-Yang Zhao; Yu-Xin Jiang; Jian-Chu Li; Zhong-Hui Xu; Qing Zhang; Na Su; Meng Yang
Journal:  Chin Med J (Engl)       Date:  2017-07-20       Impact factor: 2.628

9.  The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up.

Authors:  Maja Špiritović; Barbora Heřmánková; Sabína Oreská; Hana Štorkánová; Olga Růžičková; Lucia Vernerová; Martin Klein; Kateřina Kubínová; Hana Šmucrová; Adéla Rathouská; Petr Česák; Martin Komarc; Václav Bunc; Karel Pavelka; Ladislav Šenolt; Heřman Mann; Jiří Vencovský; Michal Tomčík
Journal:  Arthritis Res Ther       Date:  2021-06-21       Impact factor: 5.156

10.  Comparative analysis of connective tissue disease-associated interstitial lung disease and interstitial pneumonia with autoimmune features.

Authors:  Mengxue Tian; Wenhan Huang; Feifeng Ren; Lei Luo; Jun Zhou; Dongmei Huang; Lin Tang
Journal:  Clin Rheumatol       Date:  2019-11-22       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.